Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

trastuzumab (Rx)Brand and Other Names:Herceptin

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, powder for reconstitution

  • 440mg/vial
more...

Breast Cancer

Adjuvant treatment

  • Indicated for adjuvant treatment of HER-2 overexpressing breast cancer
  • Administer during and following paclitaxel, docetaxel, or docetaxel/carboplatin
  • 4 mg/kg IV over 90 minutes, THEN 
  • 2 mg/kg IV over 30 minutes qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin)
  • One week following the last weekly dose administer at 6 mg/kg as an IV infusion over 30−90 min every three weeks
  • As single agent within three wk following completion of multi-modality, anthracycline based chemotherapy regimens: Initial dose at 8 mg/kg as an IV infusion over 90 min; subsequent doses at 6 mg/kg as an IV infusion over 30−90 min every three wks
  • Extending adjuvant treatment beyond one year not recommended

Metastatic breast cancer

  • Treat as a single agent or in combination with paclitaxel
  • 4 mg/kg IV over 90 minutes, THEN 
  • 2 mg/kg IV over 30 minutes qWeek

Gastric Cancer

Indicated for treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Administered in combination with cisplatin and capecitabine or 5-fluorouracil who have not received prior treatment for metastatic disease

First cycle: 8 mg/kg IV; infuse IV over 90 min 

Subsequent cycles: 6 mg/kg IV q3wk; infuse IV over 30-90 min

Continue q3week cycles until disease progression

Dosage Modifications

Modifications required for serious adverse events, including hypersensitivity reaction (anaphylaxis), infusion reactions (fatalities), decreased left ventricular function, and pulmonary events (ARDS)

Infusion Reactions

  • Decrease infusion rate for mild-moderate infusion reactions
  • Interrupt infusion if dyspnea or clinically significant hypotension
  • Strongly consider permanent discontinuation if severe and life-threatening infusion reactions

Cardiomyopathy

  • Assess LVEF prior to initiation and frequently during treatment
  • Withhold for at least 4 weeks and repeat LVEF assessment q4Weeks for either of the following: 1) 16% absolute decrease in LVEF from pre-treatment values, 2) LVEF below institutional limits of normal and 10% absolute decrease in LVEF from pre-treatment values
  • Drug may be resumed if, within 4-8 weeks, the LVEF returns to normal and absolute decrease from baseline is 15%
  • Permanently discontinue for a persistent ( >8 weeks) LVEF decline or for suspension of drug on >3 occasions for cardiomyopathy

Dosing Considerations

Do not substitute ado-trastuzumab emtansine (Kadcyla) for or with trastuzumab (Herceptin); see Black Box Warnings

If patient has missed a dose by one week or less, usual maintenance dose (weekly schedule: 2 mg/kg; three-weekly schedule: 6 mg/kg) should be administered as soon as possible; do not wait until next planned cycle; subsequent maintenance doses should be administered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively

If patient has missed a dose by more than one week, a re-loading dose should be administered over approximately 90 min (weekly schedule: 4 mg/kg; three-weekly schedule: 8 mg/kg), as soon as possible; subsequent maintenance doses (weekly schedule: 2 mg/kg; three-weekly schedule 6 mg/kg) should be administered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively

Pancreatic Cancer (Orphan)

Indicated for the treatment of patients with pancreatic cancer that overexpress p185HER2

Orphan indication sponsor

  • Genentech, Inc; 1 DNA Way; South San Francisco, CA 94080-4990

Safety and efficacy not established

Next

Interactions

Interaction Checker

trastuzumab and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Pain (47%)

            Asthenia (42%)

            Fever (36%)

            Nausea (33%)

            Chills (32%)

            Cough (26%)

            Headache (26%)

            Diarrhea (25%)

            Vomiting (23%)

            Abdominal pain (22%)

            Back pain (22%)

            Dyspnea (22%)

            Infection (20%)

            Rash (18%)

            Anorexia (14%)

            Insomnia (14%)

            Dizziness (13%)

            1-10%

            Flu-like syndrome (10%)

            Peripheral edema (10%)

            CHF (7%)

            Depression (6%)

            Tachycardia (5%)

            UTI (5%)

            Anemia (4%)

            Hypersensitivity (3%)

            Leukopenia (3%)

            Postmarketing Reports

            Infusion reaction

            Oligohydramnios or oligohydramnios sequence, including pulmonary hypoplasia, skeletal abnormalities, and neonatal death

            Glomerulopathy

            Immune thrombocytopenia

            Previous
            Next

            Warnings

            Black Box Warnings

            Do not substitute ado-trastuzumab emtansine (Kadcyla) for or with trastuzumab (Herceptin); dosing and treatment schedules for Kadcyla and Herceptin are quite different, so confusion between these products could lead to dosing errors and potential harm to patients

            Cardiomyopathy

            • Administration can result in subclinical and clinical cardiac failure manifesting as CHF and decreased left ventricular ejection fraction (LVEF)
            • Evaluate LVEF in all patients prior to and during treatment with trastuzumab
            • Incidence and severity of left ventricular cardiac dysfunction is highest in patients who receive the drug concurrently with anthracycline-containing chemotherapy regimens
            • Discontinue if receiving adjuvant therapy for breast cancer, and strongly consider discontinuation with metastatic breast cancer who develop a clinically significant decrease in left ventricular function

            Infusion reactions, pulmonary toxicity

            • Can result in serious pulmonary toxicity and sometimes fatal infusion reactions
            • In most cases, symptoms occurred during or within 24 hr of administration
            • Interrupt infusion in patients experiencing dyspnea or clinically significant hypotension
            • Monitor until signs and symptoms completely resolve
            • Discontinue for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome

            Embryo-fetal toxicity

            • Exposure during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia, skeletal abnormalities, and neonatal death

            Contraindications

            Hypersensitivity to drug/class/component or hamster protein

            Cautions

            Use extreme cautioin in cardiac disease, cardiotoxic agent history, ejection fraction decrease, pulmonary disease, elderly

            Risk of ventricular dysfunction and CHF - strongly consider discontinuation if clinically significant decrease in left ventricular function (concurrent anthracyclines and cyclophosphamide increase incidence and severity)

            Verify pregnancy status of females of reproductive potential prior to the initiation of therapy; advise pregnant women and females of reproductive potential that therapy during pregnancy or within 7 months prior to conception can result in fetal harm; advise females of reproductive potential to avoid becoming pregnant while in therapy; if contraceptive methods are being considered, use effective contraception during treatment and for at least 7 months after receiving last dose of trastuzumab; if patient becomes pregnant while in therapy or within 7 months following last dose of therapy, apprise patient of potential hazard to fetus

            CHF: At a median follow-up duration of 8 yr, the incidence of severe CHF (NYHA III and IV) was 0.8%, and the rate of mild symptomatic and asymptomatic left ventricular dysfunction was 4.6%

            Patients who receive anthracycline after stopping trastuzumab therapy may be at increased risk of cardiac dysfunction

            Exposure to trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm; females of reproductive potential should use effective contraception during treatment and for 7 months following last dose of trastuzumab

            Possibility of severe hypersensitivity reactions (including anaphylaxis), infusion reactions, and pulmonary events - strongly consider discontinuation/suspension in patients showing signs of the above

            Preinfusion treatment

            • Symptoms such as chills and/or fever observed in ~40% of patients
            • Usually mild-to-moderate severity
            • Pretreat with acetaminophen, diphenhydramine, and meperidine (with or without reduction in infusion rate)
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D; postmarketing reports suggest that use during pregnancy increases the risk of oligohydramnios during the second and third trimesters

            Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Monoclonal antibody, inhibits growth of tumor cells that overexpress HER2

            Pharmacokinetics

            Half-life: 6 days

            Peak plasma: 377 mcg/mL

            Vd: 44 mL/kg

            Pharmacogenomics

            Mediates antibody-dependent cellular cytotoxicity against cells that overproduce HER2, and lacks effect on cells not overexpressing HER2

            HER2 testing should be performed

            Patients with breast cancers with intensive staining (3+) should definitely receive anti-HER2 therapy; the clinical relevance of 2+ staining is uncertain

            Genetic testing laboratories

            • The following companies currently offer IHC and/or FISH testing for HER2 overexpression
            • Dako (http://www.dakousa.com/)
            • Ventana Medical Systems (http://www.ventanamed.com/)
            • Vysis/Abbott Molecular (http://www.abbottmolecular.com/)
            • Invitrogen (http://www.invitrogen.com/)
            Previous
            Next

            Administration

            Incompatibilities

            Dextrose solutions

            Not to be mixed with other drugs

            IV Preparation

            Prepare each vial by reconstituting powder with 20 mL of supplied diluent (bacteriostatic water for injection [BWFI]; contains 1.1% benzyl alcohol as a preservative)

            If patient has known hypersensitivity to benzyl alcohol, drug may be reconstituted with sterile water for injection (SWI), but use SWI-reconstituted drug immediately

            Reconstituted vial yields 21 mg/mL

            Using a sterile syringe, slowly inject the 20 mL of diluent into the vial containing the lyophilized cake; the stream of diluent should be directed into the lyophilized cake

            Do not shake; swirl the vial gently to aid reconstitution

            Slight foaming of the product may be present upon reconstitution; allow the vial to stand undisturbed for ~5 minutes

            The solution should be free of visible particulates, clear to slightly opalescent and colorless to pale yellow

            Further dilution

            • Withdraw calculated dose from reconstituted vial and add to infusion bag containing 250 mL 0.9% NaCl
            • Gently invert the bag to mix the solution

            IV Administration

            Not for IV push or bolus administration

            Administer initial IV infusion over 90 min

            Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated

            Missed dose

            • Missed dose by ≤1 week: Usual maintenance dose (weekly schedule: 2 mg/kg; 3-weekly schedule: 6 mg/kg) should be administered as soon as possible; do not wait until the next planned cycle; give subsequent scheduled doses 7 or 21 days later accordingly
            • Missed dose by >1 week: Reloading dose should be administered over ~90 minutes (weekly schedule: 4 mg/kg; three-weekly schedule: 8 mg/kg), as soon as possible; do not wait until the next planned cycle; give subsequent scheduled doses 7 or 21 days later accordingly

            Storage

            Do not freeze

            Unopened vials: Stable at 2-8°C (36-46°F) prior to reconstitution

            Reconstituted vials with BWFI: Once reconstituted with BWFI, may be stored in refrigerator (2-8°C) for 28 days

            Reconstituted vials with SWI: Vials reconstituted with unpreserved SWI (not supplied) should be used immediately and not stored

            Diluted solution: May be refrigerated (2-8°C) for up to 24 hr

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.